Incyte Corp: (NASD: INCY)
$23.04
-0.13 (-0.56%)
Volume 809,187
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 22.74 - 23.43 |
| 52wk Low - High | 15.43 - 26.30 |
| Previous Close | 23.17 |
| Avg. Volume | 938,757 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 3.08 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 2.17 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.14 |
| Quarterly Earnings ESP |
-10.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Outperform |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.14 |
| Current Quarter Estimate | 0.10 |
| Most Accurate Estimate | 0.09 |
| Earnings ESP |
-10.00% |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.12 |
| Expected Earnings Growth | NA |
Company Description
Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.10 | 0.07 | -0.14 | 0.25 |
| Number of Estimates | 8 | 7 | 9 | 9 |
| Low Estimate | -0.04 | -0.17 | -0.43 | -0.28 |
| High Estimate | 0.38 | 0.29 | 0.27 | NA |
| Year Ago EPS | 0.03 | -0.17 | -0.34 | -0.14 |
| EPS Growth | 241.67% | 142.02% | 60.13% | 287.70% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| INCYTE CORP | INCY | 23.04 | |
|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Alnylam Narrows Loss, Sales Fall
May 07, 2013
Arena Pharma Narrows Loss
May 06, 2013
Narrower-Than-Expected Loss at Incyte
May 03, 2013
The Zacks Analyst Blog Highlights: AT&T, Optimer Pharmaceuticals, ViroPharma, Astellas Pharma and Incyte
May 02, 2013
Optimer's Dificid Cleared Down Under
May 01, 2013
BioMarin Widens Loss, Maintains View
Apr 29, 2013
Revenues Rise at Incyte
Feb 15, 2013
Update on Lilly's Tabalumab
Feb 11, 2013
Financials
| EPS TTM | -0.12 |
| Sales | 297 |
| Net Income | -15 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 9.29 |
News
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Incyte Is Up 7.3% (INCY) - Financial News Network Online - Earnings Lookback
May 18, 2013
Incyte (INCY) Showing Bullish Technicals But Could Break Through $24.77 Resistance - Freshbrewedmedia
May 16, 2013
Buyers Accumulate Shares of Incyte, Up 2.3% - Financial News Network Online - Market Movers
May 14, 2013
Incyte (INCY) Showing Bullish Technicals But Could Break Through $22.98 Resistance - Freshbrewedmedia
May 10, 2013
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and Upcoming Deadline -- INCY - Globenewswire
May 10, 2013
Incyte Crosses Above its 10-day MA (INCY) - Financial News Network Online - Moving Average Crossovers
May 9, 2013
Is the Biggest Pharma Company in the World the Best Investment? - TheMotleyFool
May 7, 2013
Shares of Incyte Under Pressure, Down 1.5% - Financial News Network Online - Market Movers
May 7, 2013
Broker Recommendations
| Current ABR | 1.49 |
| ABR (Last Week) | 1.49 |
| # of recs in ABR | 15 |
| Average Target Price | 25.75 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | 36 out of 155 |
